Roche: Ventana PD-L1 test approved in the US

(CercleFinance.com) - Roche announces that the Roche Ventana PD-L1 test (SP142) has been approved by the US Food and Drug Administration as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane.


PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer.

"Each year about 300,000 women are diagnosed globally with triple-negative breast cancer, an aggressive disease with limited treatment options that represents 15 percent of all breast cancer cases," the group said. "This approval is an important step in Roche's personalized healthcare strategy to fit treatments to patients who can benefit most from a specific medicine," management added.



Copyright (c) 2019 CercleFinance.com. All rights reserved.